ClinicalTrials.gg
RecruitingNCT05159349Updated Jun 8, 2026

Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia

An observational study in Schizophrenia, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Shanghai Mental Health Center · Observational

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Schizophrenia by Shanghai Mental Health Center — 15 open to participants now, 15 under way, none of them phase 3. Schizophrenia · Shanghai Mental Health Center.

Planned enrollment
4th of 11
1,200 · median 480
Started
2021
with 4 others
Observational
11 of 61
4 open now
Primary completion
2027-11
later than 8 of 14 live
Registered
38th of 61
by date

Among the 61 studies in Schizophrenia by Shanghai Mental Health Center, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2021, is one of 11 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 38th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

15 of the 61 studies in Schizophrenia by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Schizophrenia by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

Schizophrenia is one of the components of severe mental disorders. It has the characteristics of prolonged course, low cure rate, high recurrence rate and high disability rate. It brings many short-term and long-term effects to individuals, families and society. Studies on patients with schizophrenia mainly focus on cross-sectional and case-control studies, but there is a lack of long-term follow-up of patients with schizophrenia in the community. Therefore, this study would establish a cohort study to solve the chronological relationship between exposure and effect, focus on community schizophrenia, and establish a community schizophrenia patient biobank that has been tracked for a long time from diagnosis.

Read the detailed description

Schizophrenia is one of the components of severe mental disorders. It has the characteristics of prolonged course, low cure rate, high recurrence rate and high disability rate. It brings many short-term and long-term effects to individuals, families and society.Studies on patients with schizophrenia mainly focus on cross-sectional and case-control studies, but there is a lack of long-term follow-up of patients with schizophrenia in the community. Therefore, this study would establish a cohort study to solve the chronological relationship between exposure and effect, focus on community schizophrenia, and establish a community schizophrenia patient biobank that has been tracked for a long time from diagnosis.

  1. Aim of the study:

    1.1 Based on previous studies, this study will focus on patients with schizophrenia in the community. Establishing a biobank of new cases to monitor the occurrence of disease recurrences, violent behaviours and other outcome events during the whole life cycle of schizophrenia patients. Exploring the predictive effects of biological, psychosocial, imaging and other indicators on patient recurrence and other events.

    1.2 At the same time, establishing a sample database of patients with schizophrenia in the community to lay a working foundation and reserve sample resources for subsequent related mechanism research, drug research, and intervention research.

  2. Content of the study 2.1 At least 1,200 patients with schizophrenia diagnosed within five years will be recruited. On the basis of community follow-up and health examination, this study will expand biological sample collection and professional scale evaluation, establish a schizophrenia community cohort.

    2.2 Based on the establishment of the cohort, this study will carry out statistical description according to the type of data. The differences will be compared between the exposed group and the unexposed group in demographic information, family and past disease history, personal living habits, condition and treatment, psychological evaluation, social support evaluation, sleep quality, functional evaluation, quality of life and other content. Repeated measures analysis of variance will be used to compare the differences in blood pressure, blood glucose and other indicators between the exposed group and the unexposed group. The generalized estimating equation will be used to analyze the relationship between the outcome of recurrence and emergency about physical activity, related biochemical indicators, and social support. On the basis of statistical results, this study will carry out research on the prognostic factors and related physiological mechanisms of schizophrenia.

  3. Study design 3.1 Pay attention to multiple prognostic outcomes such as relapse, dangerous behaviours, suicide and self-harm, calculate the included sample size based on this. After the start of the project, in Hongkou, Jinshan, Minhang, and Xuhui districts, all schizophrenic patients in management who meet the inclusion criteria will be continuously included in the district.

3.2 At baseline, the patient's demographic information and a complete health history (include personal history, family history, and medical history) will be taken. The questionnaire survey includes the Brief Psychiatric Rating Scale (BPRS),the Patient Health Questionnaire-9 (PHQ-9),the Generalized Anxiety Disorder Screener (GAD-7), the Pittsburgh Sleep Quality Index (PSQI) , the WHO Quality of Life Scale-Brief (WHOQOL-BREF) , the Modified Overt Aggression Scale (MOAS), the 10-item social disability screening schedule (SDSS) and the Perceived social support scale(PSSS),etc. Within six months of the completion of the baseline survey, the district-level mental health center arranges for patients in the district to participate in physical examinations. All measures will be administered at baseline and 12, 24, 36 ,48 and 60 months follow-up except for the health history and PSSS, which will be administered only at baseline. Besides, the study will focus on the patients' recurrence events, violent behavior, various impacts on society and family, emergency response events, and prognosis by carrying out active follow-up every three months.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Cohort study
  • The whole life cycle
  • Mental health
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Since the start of the project, all schizophrenia patients in management who meet the inclusion criteria in this district have been continuously included in Hongkou, Jinshan, Minhang, and Xuhui districts, and at least 300 patients in each district will be included until the corresponding sample size is reached.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Registered in the Shanghai Mental Health Information Management System.
  • Meets criteria for the diagnosis of schizophrenia (ICD-10 or ICD-11).
  • Patients with schizophrenia diagnosed within five years.
  • Aged between 18 and 65 years.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe physical diseases and organic brain diseases.
  • The patient is about to settle outside Shanghai.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Exposed group
  • Non-exposed group
06

What researchers measure

Primary outcomes

  1. 1-year BPRS reduction rate

    The Brief Psychiatric Rating Scale (BPRS) was used to measure the presence and severity of psychiatric symptoms entailing positive symptoms, general psychopathology, and affective symptoms (e.g., thought disturbance, emotional withdrawal, hostility, and suspiciousness) for patients with mental illness, particularly schizophrenia. Each of the 18 items are designed to represent a discrete symptom area. Items are rated on a 7-point Likert scale, from 1 = "not present" to 7 = "extremely severe", with scores ranging from 18 to 126 (achieved through summing the item scores). Higher scores indicated more severity of psychiatric symptoms. Reduction rate was calculated using the following formula: reduction rate= (Score before treatment - Score after treatment)/(Score before treatment - 18) × 100%. A reduction rate of BPRS score \> 25% was considered as a clinically meaningful improvement.

    Time frame: Change from Baseline BPRS at 12 months

  2. 2-year BPRS reduction rate

    The BPRS reduction rate during the 2-year follow-up period.

    Time frame: Change from Baseline BPRS at 24 months

  3. 3-year BPRS reduction rate

    The BPRS reduction rate during the 3-year follow-up period.

    Time frame: Change from Baseline BPRS at 36 months

  4. 4-year BPRS reduction rate

    The BPRS reduction rate during the 4-year follow-up period.

    Time frame: Change from Baseline BPRS at 48 months

  5. 5-year BPRS reduction rate

    The BPRS reduction rate during the 5-year follow-up period.

    Time frame: Change from Baseline BPRS at 60 months

Secondary outcomes

  1. MOAS

    The Modified Overt Aggression Scale (MOAS) is a four-part behavior rating scale used to evaluate and document the "frequency and severity" of aggressive episodes. The rating scale is made up of four categories; verbal aggression, aggression against objects, aggression against self, and aggression against others. Each category consists of five responses, which over time can track the patient's aggressive behavior. The MOAS is one of the most widely used measures for violence and aggression, with 4 items in total, 0\~4 points for each item.

    Time frame: Change from Baseline MOAS at 12 months, 24 months, 36 months, 48 months, and 60 months

  2. WHOQOL-BREF

    The WHO Quality of Life Scale-Brief (WHOQOL-BREF) was developed by the Word Health Organisation as a quality of life assessment that would be applicable cross-culturally. It is a 26 item self report measure, especially useful for measuring outcomes with adults with a psychosocial disability. The WHOQOL-BREF measures four factors: physical health, psychological Health, social relationships, and environment. The total score is presented between 26 and 156, where higher scores represent higher levels of quality of life.

    Time frame: Change from Baseline WHOQOL-BREF at 12 months, 24 months, 36 months, 48 months, and 60 months

  3. GAD-7

    The Generalized Anxiety Disorder Screener (GAD-7) is a brief, 7-item self-report measure for anxiety symptoms in adolescents and adults. Although developed primarily as a screening tool for GAD, it can also be used as a diagnostic tool to monitor changes in symptoms over time, and as a screener for social anxiety, panic disorder, and post-traumatic stress disorder. Each item is rated on a likert-type scale from zero ("not at all") to three ("nearly every day"), with total scores ranging from 0 to 21.

    Time frame: Change from Baseline GAD-7 at 12 months, 24 months, 36 months, 48 months, and 60 months

  4. PHQ-9

    The Patient Health Questionnaire-9 (PHQ-9) is a multipurpose instrument for screening , diagnosing , monitoring and measuring the severity of depression. The tool rates the frequency of the symptoms which factors into the scoring severity index. The PHQ -9 is brief and useful in clinical practice. The PHQ -9 can be administered repeatedly , which can reflect improvement or worsening of depression in response to treatment .Each item is rated on a likert-type scale from zero ("not at all") to three ("nearly every day").

    Time frame: Change from Baseline PHQ-9 at 12 months, 24 months, 36 months, 48 months, and 60 months

  5. PSQI

    The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month. The questionnaire consists of a combination of Likert- type and open-ended questions. Respondents are asked to indicate how frequently they have experienced certain sleep difficulties over the past month and to rate their overall sleep quality. Scores for each question range from 0 to 3, with higher scores indicating more acute sleep disturbances.

    Time frame: Change from Baseline PSQI at 12 months, 24 months, 36 months, 48 months, and 60 months

  6. SDSS

    The 10-item social disability screening schedule (SDSS) was used for measuring social function. It is a shortened version of psychiatric disability assessment schedule (DAS). SDSS was used to evaluate social disability, with 10 items in total, 0\~2 points for each item.

    Time frame: Change from Baseline SDSS at 12 months,24 months, 36 months, 48 months, and 60 months

Other outcomes

  1. 1-year Rate of rehospitalization

    Relapse of patients with schizophrenia is defined as a clinical deterioration or an exacerbation of symptoms based on rehospitalization. Data from the Shanghai Mental Health Work Website.

    Time frame: The rehospitalization rate from Baseline during the 1-year follow-up period.

  2. 2-year Rate of rehospitalization

    The rehospitalization rate from Baseline during the 2-year follow-up period.

    Time frame: From Baseline during the 2-year follow-up period.

  3. 3-year Rate of rehospitalization

    The rehospitalization rate from Baseline during the 3-year follow-up period.

    Time frame: From Baseline during the 3-year follow-up period.

  4. 4-year Rate of rehospitalization

    The rehospitalization rate from Baseline during the 4-year follow-up period.

    Time frame: From Baseline during the 4-year follow-up period.

  5. 5-year Rate of rehospitalization

    The rehospitalization rate from Baseline during the 5-year follow-up period.

    Time frame: From Baseline during the 5-year follow-up period.

  6. 1-year the number of violent incidents

    The primary health provider will follow up the patients every 3 months. If they learn about the violent behavior of the patient with schizophrenia during the follow-up process, they will record them on the Shanghai Mental Health Work Website.

    Time frame: From Baseline during the 1-year follow-up period.

  7. 2-year the number of violent incidents

    2-year the number of violent incidents

    Time frame: From Baseline during the 2-year follow-up period.

  8. 3-year the number of violent incidents

    3-year the number of violent incidents

    Time frame: From Baseline during the 3-year follow-up period.

  9. 4-year the number of violent incidents

    4-year the number of violent incidents

    Time frame: From Baseline during the 4-year follow-up period.

  10. 5-year the number of violent incidents

    5-year the number of violent incidents

    Time frame: From Baseline during the 5-year follow-up period.

  11. 1-year the number of suicides

    The primary health provider will follow up the patients every 3 months. If they learn about the suicide in individuals with schizophrenia during the follow-up process, they will record them on the Shanghai Mental Health Work Website.

    Time frame: From Baseline during the 1-year follow-up period.

  12. 2-year the number of suicides

    2-year the number of suicides

    Time frame: From Baseline during the 2-year follow-up period.

  13. 3-year the number of suicides

    3-year the number of suicides

    Time frame: From Baseline during the 3-year follow-up period.

  14. 4-year the number of suicides

    4-year the number of suicides

    Time frame: From Baseline during the 4-year follow-up period.

  15. 5-year the number of suicides

    5-year the number of suicides

    Time frame: From Baseline during the 5-year follow-up period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Nov 2027, 71 months after the start.

Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's planned 71 months is above that.

Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2021
First posted
Dec 16, 2021
StartActual
Dec 1, 2021
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05159349
Collaborators
Fudan University
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Dec 1, 2021
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Weibo Zhang
Contact
zhangweibo600@163.com
86-18918516651
Jun Cai
study director · Shanghai Mental Health Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion